Learning Library Video
Tesamorelin: 15% Less Visceral Fat in an HIV Trial
Source domain: www.youtube.com
Video from Travis Woodley
Short, 0:46. Published November 9, 2026. Travis Woodley, MSN, RN, CRNP. Series: Peptides.
A 26-week trial in 412 adults with HIV and excess abdominal fat measured about a 15% decrease in visceral fat with tesamorelin versus about a 5% increase with placebo. This was a CT-measured fat compartment, not a 15% reduction in body weight.
The approved indication is excess abdominal fat in adults with HIV-associated lipodystrophy. Extension research found visceral fat returning after treatment stopped. Individual clinical review includes contraindications and glucose/IGF-1 monitoring.
More short answers
Educational only, not personal medical advice. Discuss treatment and supplement decisions with your qualified clinician.